Clinical trial
Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in…
NCT00333034 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00333034 |
|---|---|
| Title | Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis |
| Official title | A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 120 |
| Start date | Jun 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Jun 2, 2006 |
| Last update posted | Dec 6, 2007 |
| Countries | Austria, Belgium, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: